|
|
 |
|
Viewing report
|
|
|
|
European Cell Based Assays Markets
Frost & Sullivan, Feb 2008, Pages: 82
This Frost & Sullivan research service titled European Cell Based Assays Markets provides an overview of the cell based assay market in drug discovery, together with its revenues. The study provides a complete analysis of key market drivers, challenges and trends in the market. Finally, it provides strategic solutions for vendors hoping to gain advantage in this growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: cell growth associated assay kits, cell death associated assay kits and functional assay kits.
Market Overview
European Cell Based Assays Markets Face a Tough Challenge in Identifying Novel Drug Candidates in Drug Discovery
With the current estimates placing the cost to develop a drug from concept at more than $800 million and a time period of ten years, the benefits of being the first to market a new drug onto the market is fast becoming a high risk business for pharmaceutical and biotechnology companies. Pharma companies are continually in search of new strategies to gain better information about drug candidates as early as possible in lead discovery and lead optimisation. Problems such as pharmacokinetics/ADME (40 per cent), animal toxicity (10 per cent) and side effects/human toxicity (10 per cent) are some of the challenges that these companies are facing with the failure of drug candidates. One effective strategy used in the pharmaceutical and biotechnology industries is to identify new drug candidates by high throughput screening (HTS).
'To date, HTS laboratories use cell based assays as primary detection tools to screen potential drug candidates, providing more accurate representation of the real-life cell model than the traditional biochemical assays,' explains the analyst of this research. 'The objective of HTS is to reduce the number of lead compounds to those showing true potential of becoming genuine drug candidates, with recent attention on cytotoxicity tests.' The surge in demand for more toxicity tests has come about in response to pharmaceutical companies striving to improve the cost effectiveness of their drug candidate programmes. Another emerging trend in the European cell based assay market is the pressing need for direct and accurate means for screening potential drug compounds against GPCR targets, as they account for more than 60 per cent of the prescription drugs in the market at present. Research has found that the industry is willing to invest in novel technologies and advances in drug discovery, moving towards a combination of cell biology, imaging and in vivo skills.
Advances in Lab Disciplines, Novel Technologies and Detection Methods in Cell Based Assay Market Hold Great Promise for the Discovery of New Drug Candidates
Cell based assays are used to detect the failure of drug candidates at the early stages of drug development, helping reduce the costs associated with developing the drug in the long term. The trends towards assay miniaturisation and multiplexing for high throughput and ultra-high throughput screening continue to spur the development of homogeneous cell based assays in high-density, small-volume microplate formats.
The European cell based assay market was estimated at $238 million in 2007, with the cell based assay kit market accounting for 27.8 per cent of the total ($66 million). 'Research has shown that fluorescence labelling and advanced detection methods have given the cell based assay market a huge boost over the last five years, maintaining a growth rate of 18.0 per cent in Europe, with the total cell based assay kit market likely to reach over $110 million by 2010,' states the analyst. 'Recently, the cell based assay market has witnessed market participants expanding their range of reagent portfolio and instrumentation platform in the area of drug discovery to meet end-user demand, with immense interaction among lab disciplines (use of reagents/consumables, assay kits and mixed cell types), technology platforms (imaging, microscopy and flow cytometry) and detection methods (absorbance, fluorescence and luminescence).' Another emerging trend is the outsourcing of several cell based assay activities by HTS researchers to reduce costs and utilise the expertise of companies in various R&D areas and compressing the time line for drug development.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
-Cell growth associated assay kits
-Cell death associated assay kits
-Cell functional assay kits
Customers who bought this item also bought
Cell-Based Assays for Drug Discovery
U.S. Cell-Based Assays Markets
Development of Cell-Based Assays (Technical Insights)
Overview of the European Drug Discovery Market
Validation of Cell-Based Assays in the GLP Setting: A Practical Guide
A Guide to HTS Assay Development
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Cell Therapy - Technologies, Markets and Companies
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Developments in Stem Cell Research
Cell-Based Assays: Commercial Opportunities, Legal Trends, and Technology Analyses
Stem Cell Research 2008
|
|
|
|
